Results 21 to 30 of about 23,172 (159)

Posttransplant Lymphoproliferative Disorders [PDF]

open access: yesAdvances in Hematology, 2012
Posttransplant lymphoproliferative disorders (PTLDs) are a group of diseases that range from benign polyclonal to malignant monoclonal lymphoid proliferations. They arise secondary to treatment with immunosuppressive drugs given to prevent transplant rejection.
Hazem Ibrahim, Kikkeri N. Naresh
openaire   +4 more sources

Case for diagnosis. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2019
: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a rare disease, with an indolent evolution and benign course. The classic presentation is a solitary nodule on the face or trunk.
Flávia de Oliveira Valentim   +2 more
doaj   +1 more source

An Uncommon Case of Eosinophilic Myocarditis in a Patient With Autoimmune Lymphoproliferative Syndrome

open access: yesAnnals of Internal Medicine: Clinical Cases
Eosinophilic myocarditis is a rare but well-described inflammatory condition with high morbidity and mortality but is not reported as caused by underlying autoimmune lymphoproliferative disorder.
Maria T. Gamero   +6 more
doaj   +1 more source

Case of a young girl with marked bone marrow plasmacytosis

open access: yesSri Lanka Journal of Medicine, 2021
Marked plasmacytosis in the bone marrow is a rare finding in young people. If present it is secondary to an underlying disease condition. Castleman disease is a rare form of lymphoproliferative disorder. Due to its rarity, it is not frequently considered
V. C. Panditha Gunwardena   +4 more
doaj   +1 more source

A case of posttransplant lymphoproliferative disorder

open access: yesJournal of Marine Medical Society, 2017
Posttransplant lymphoproliferative disorders (PTLDs) are life-threatening complications of solid-organ and bone marrow transplantations leading to a high mortality. PTLD represents a heterogeneous group of lymphoproliferative diseases.
G S Chowdhary   +2 more
doaj   +1 more source

A response of rituximab plus lenalidomide therapy in patients with post-transplant lymphoproliferative disease and methotrexate-related lymphoproliferative disorder in the central nervous system: a case report

open access: yesJournal of Medical Case Reports
Background Post-transplant lymphoproliferative disorder and methotrexate-related lymphoproliferative disorder are rare complications normally with unfavorable prognosis. Post-transplant lymphoproliferative disorder of the central nervous system is a rare
Hanguo Guo, Hong Zhang, Wenyu Li
doaj   +1 more source

A Rare Case of Primary Cutaneous CD4+ Small/Medium Size T-Cell Lymphoproliferative Disorder Responding to Rituximab

open access: yesCase Reports in Dermatology
Introduction: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder is a rare lymphoproliferative disorder (PCS-TCLPD) characterized by a solitary erythematous plaque or nodule on the face, neck, or upper trunk with a ...
Saman Al-Zahawi   +5 more
doaj   +1 more source

Primary central nervous system post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation: a case report

open access: yesFrontiers in Oncology
PurposePrimary central nervous system, diffuse large B-cell lymphoma, post-transplant lymphoproliferative disorder in the cerebellopontine angle after an allogeneic stem cell transplantation has never been reported in the literature.
Margaret Tugend   +4 more
doaj   +1 more source

Post-kidney transplant large bowel lymphoproliferative disorder

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2014
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation. The gastrointestinal (GI) tract is a common site involved, but non-specific signs and symptoms often delay the ...
Neeraj Singh, Singh Samavedi, Amer Rajab
doaj   +1 more source

Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report

open access: yesJournal of Medical Case Reports, 2023
Background Hypoproliferative anemia is a frequently encountered adverse event in cancer patients receiving immune checkpoint inhibitors (ICI). Secondary pure red cell aplasia (PRCA) is a rare but recognized immune related adverse event.
Vaibhav Kumar   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy